TITLE

Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor

AUTHOR(S)
Stolk, J; Camps, J; Feitsma, H I; Hermans, J; Dijkman, J H; Pauwels, E K
PUB. DATE
June 1995
SOURCE
Thorax;Jun1995, Vol. 50 Issue 6, p645
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
No abstract available.
ACCESSION #
66080702

 

Related Articles

  • Production of secretory leucocyte protease inhibitor (SLPI) in human pancreatic beta-cells. Nystrom, Max; Bergenfeldt, Magnus; Ljungcrantz, Irena; Lindeheim, Asa; Ohlsson, Kjell // Mediators of Inflammation;Jun99, Vol. 8 Issue 3, p147 

    SECRETORY leucocyte protease inhibitor (SLPI) is a potent inhibitor of granulocyte elastase and cathepsin G, and also an inhibitor of pancreatic enzymes like trypsin, chymotrypsin and pancreatic elastase. SLPI has also been shown to inhibit HIV-1 infections by blocking viral DNA synthesis. Since...

  • Novel distribution of the secretory leucocyte proteinase inhibitor in kidney. Ohlsson, Sophie; Ljungkrantz, Irena; Ohlsson, Kjell; Segelmark, Mårten; Wieslander, Jörgen // Mediators of Inflammation;Nov2001, Vol. 10 Issue 6, p347 

    THE secretory leucocyte proteinase inhibitor (SLPI) is a low molecular weight, tissue-specific inhibitor of, for example, elastase and cathepsin G, which also have antimicrobial capacity. SLPI has been localised to the respiratory, gastrointestinal and genital tracts, but so far not to the...

  • Androgen Receptor Signaling in Prostate Cancer: New Twists for an Old Pathway. Junjie Feng; Zheng, S. Lilly; Wennuan Liu; Isaacs, William B.; Jianfeng Xu // Journal of Steroids & Hormonal Science;Special2012, Vol. 3 Issue S, Special section p1 

    Secretory leukocyte protease inhibitor is a multifunctional protein with a variety of activities attributed to it. A significant increase in the expression of Secretory leukocyte protease inhibitor was noticed in syncytiotrophoblasts following differentiation of cytotrophoblasts in to...

  • Pulmonary Gene Silencing in Transgenic EGFP Mice Using Aerosolised Chitosan/siRNA Nanoparticles. Nielsen, Ebbe; Nielsen, Jan; Becker, Daniel; Karlas, Alexander; Prakash, Hridayesh; Glud, Sys; Merrison, Jonathan; Besenbacher, Flemming; Meyer, Thomas; Kjems, Jørgen; Howard, Kenneth // Pharmaceutical Research;Dec2010, Vol. 27 Issue 12, p2520 

    Purpose: This work describes the production and application of an aerosolised formulation of chitosan nanoparticles for improved pulmonary siRNA delivery and gene silencing in mice. Methods: Aerosolised chitosan/siRNA nanoparticles were pneumatically formed using a nebulising catheter and sized...

  • Beneficial effects of secretory leukocyte protease inhibitor after spinal cord injury. Ghasemlou, Nader; Bouhy, Delphine; Yang, Jingxuan; López-Vales, Rubèn; Haber, Michael; Thuraisingam, Thusanth; He, Guoan; Radzioch, Danuta; Ding, Aihao; David, Samuel // Brain: A Journal of Neurology;Jan2010, Vol. 133 Issue 1, p126 

    Secretory leukocyte protease inhibitor is a serine protease inhibitor produced by various cell types, including neutrophils and activated macrophages, and has anti-inflammatory properties. It has been shown to promote wound healing in the skin and other non-neural tissues, however, its role in...

  • HIV-Protease Inhibitors Reduce Cell Adherence of Candida Albicans Strains by Inhibition of Yeast Secreted Aspartic Proteases. von Zepelin, Margarete Borg-.; Meyer, Ingo; Thomssen, Reiner; Würzner, Reinhard; Sanglard, Dominique; Telenti, Amalio; Monod, Michel // Journal of Investigative Dermatology;Nov99, Vol. 113 Issue 5, p0 

    Since the introduction of new anti-retroviral agents such as human immunodeficiency virus (HIV) protease inhibitors, oropharyngeal candidiasis is less often observed in acquired immune deficiency syndrome patients. Secretory aspartic proteases of Candida albicans, which have similarities to the...

  • Proteases Essential for Human Influenza Virus Entry into Cells and Their Inhibitors as Potential Therapeutic Agents. Kido, Hiroshi; Okumura, Yuushi; Yamada, Hiroshi; Trong Quang Le; Yano, Mihiro // Current Pharmaceutical Design;Feb2007, Vol. 13 Issue 4, p405 

    Influenza A virus (IAV) is one of the most common infectious pathogens in humans. Since IVA genome does not have the processing protease for the viral membrane fusion glycoprotein precursors, entry of this virus into cells is determined primarily by host cellular, trypsin-type, processing...

  • Proteases Essential for Human Influenza Virus Entry into Cells and Their Inhibitors as Potential Therapeutic Agents. Kido, Hiroshi; Okumura, Yuushi; Yamada, Hiroshi; Quang Le, Trong; Yano, Mihiro // Current Pharmaceutical Design;Jan2007, Vol. 13 Issue 3, p403 

    Influenza A virus (IAV) is one of the most common infectious pathogens in humans. Since IVA genome does not have the processing protease for the viral membrane fusion glycoprotein precursors, entry of this virus into cells is determined primarily by host cellular, trypsin-type, processing...

  • Coumarin and Isocoumarin as Serine Protease Inhibitors. Pochet, Lionel; Frédérick, Raphaël; Masereel, Bernard // Current Pharmaceutical Design;Nov2004, Vol. 10 Issue 30, p3781 

    Serine proteases are attractive targets for the design of enzyme inhibitors since they are involved in the etiology of several diseases. Within the class of serine proteases, HLE is one of the most destructive enzymes in the body. It is implicated in the promotion or exacerbation of a number of...

  • AIDS update: How saliva thwarts HIV. Rudavksy, Shari // Self;Jul95, Vol. 17 Issue 7, p54 

    Reports on a study which looked at why AIDS is hardly ever transmitted through kissing. Secretory leukocyte protease inhibitor (SLPI) protein in saliva as the cause; Presence of SLPI in cervical mucus.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics